Phase 2 Lymphoma Trial, Recruiting NCT06876688 Sponsor: Ruijin Hospital Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT06876688
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older, of any gender
  • People with a type of large B-cell lymphoma that involves the central nervous system (brain/spinal cord), which has come back or stopped responding to treatment after at least one prior treatment, and who have shown a complete or partial response to follow-up treatment with a currently stable status
  • People with a general health score of 0–2 on a standard medical scale (meaning able to carry out daily activities with little to no limitation) (confirm with trial site)
  • People with a life expectancy of at least 12 weeks
  • People who are willing and able to use contraception during the trial
  • People whose blood counts and organ function meet specific minimum levels, including adequate white blood cell counts, haemoglobin, platelets, liver function, kidney function, and pancreatic enzyme levels (confirm with trial site for exact thresholds)

Who may not be able to join:

  • People with severe, active symptoms affecting the central nervous system (brain or spinal cord)
  • People who have previously received a type of immune cell therapy called CAR-T therapy that targets the CD19 protein
  • People known to have HIV infection or who test positive for HIV
  • People who have received a live vaccine within 30 days before the study treatment is due to start
  • People who have an active autoimmune disease that required whole-body (systemic) treatment within the past 12 months
  • People with a known allergy to the study drug, or a history of severe allergic reactions
  • People considered to have a significant risk of dangerous irregular heart rhythms
  • People who have had a stroke or bleeding in the brain within the 3 months before starting the study drug
  • People who have, or have had within the past 3 years, another type of cancer
  • People whose overall health circumstances, in the treating doctor's judgement, could interfere with safe or meaningful participation in the trial
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 13564230293

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
30 November 2023
Est. completion
30 November 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete response rate(CRR) at 3-month

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov